Montair 10 mg is indicated for:

• Prophylaxis and chronic treatment of asthma
• Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
• Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis

Adults and adolescents with asthma or seasonal allergic rhinitis: 

• The dosage for adults and adolescents 15 years of age and older: Monas 10 mg tablet once daily.

Pediatric patients with asthma or seasonal allergic rhinitis:

• The dosage for pediatric patients 6 to 14 years of age: Monas 5 mg tablet once daily.
• The dosage for pediatric patients 2 years to 5 years of age: Monas 4 mg tablet once daily.
• The dosage for pediatric patients 6 months to 5 years of age: Monas 4 mg oral granules once daily. This can be administered either directly in the mouth, or mixed with a spoonful of cold water or soft food at room temperature

Use in the pediatric patient: The safety and efficacy of Monas have been established in adequate and well-controlled studies in pediatric patients with asthma 6 months to 14 years of age. Safety and efficacy profiles in this age group are similar to those seen in adults.

Hepatic Insufficiency: No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.

Renal Insufficiency: No dosage adjustment is recommended in patients with renal insufficiency.

Elderly use: The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of Monas are similar in elderly and younger adults. The plasma half-life of Monas is slightly longer in the elderly. No dosage adjustment in the elderly is required.